Related Experiment Videos
Does carbamazepine have a narrow therapeutic plasma concentration range?
M Bialer1, R H Levy, E Perucca
1Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Israel.
Therapeutic Drug Monitoring
|March 5, 1998
Summary
Carbamazepine is classified as a narrow therapeutic index (NTI) drug, meaning it has a small window between effective and toxic doses. This study critically evaluates the evidence supporting carbamazepine
Area of Science:
- Pharmacology
- Clinical Pharmacy
- Drug Safety
Background:
- Recent discussions have focused on classifying drugs based on their therapeutic index (TI).
- Drugs with a TI < 2 are defined as narrow therapeutic index (NTI) drugs.
- Carbamazepine is one such agent currently classified as an NTI drug.
Purpose of the Study:
- To critically evaluate the evidence supporting carbamazepine's classification as an NTI drug.
- To address the long-standing question of whether carbamazepine truly possesses a narrow therapeutic plasma concentration range.
Main Methods:
- Review of existing literature and clinical data on carbamazepine.
- Analysis of pharmacokinetic and pharmacodynamic data related to carbamazepine.
- Critical assessment of studies defining therapeutic ranges and TI for carbamazepine.
Main Results:
- Evidence supporting carbamazepine's NTI classification requires critical re-evaluation.
- Plasma concentration variability and its clinical impact need further investigation.
- Existing data may not definitively establish a narrow therapeutic plasma concentration range for carbamazepine.
Conclusions:
- The classification of carbamazepine as an NTI drug warrants further scrutiny.
- A comprehensive review is needed to confirm or refute its narrow therapeutic index.
- Clarifying carbamazepine's therapeutic index is crucial for optimizing patient safety and treatment efficacy.